---
title: "Altice USA posts $2.11 billion revenue and $1.63 billion net loss in Q3 2025"
description: "Altice USA reported a Q3 2025 revenue of $2.11 billion but faced a net loss of $1.63 billion, significantly higher than the $43 million loss in the same period of 2024. The net loss per share rose to "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264641130.md"
published_at: "2025-11-06T12:01:43.000Z"
---

# Altice USA posts $2.11 billion revenue and $1.63 billion net loss in Q3 2025

> Altice USA reported a Q3 2025 revenue of $2.11 billion but faced a net loss of $1.63 billion, significantly higher than the $43 million loss in the same period of 2024. The net loss per share rose to $3.47 from $0.09 year-over-year. The company’s total debt is $26.4 billion, with net debt at $25.4 billion. Despite reaching over 700,000 fiber customers and achieving record gross margins, Altice noted challenges in broadband subscriber growth due to competition and a low-growth environment.

Altice USA reported a net loss attributable to stockholders of $1.6 billion for the nine months ended September 30, 2025, compared to a net loss of $43.0 million in the same period of 2024. Basic and diluted net loss per share was $3.47 for the third quarter of 2025, up from $0.09 in the prior year quarter. Depreciation and amortization totaled $1.2 billion, up from $1.2 billion a year earlier. The company’s total debt stood at $26.4 billion with net debt including finance leases at $25.4 billion. Altice USA reached over 700,000 fiber customers during the quarter and reported record gross margin performance, but noted softer broadband subscriber trends due to increased competition and a low-growth environment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altice USA Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106034338) on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [ATUS.US - Altice USA ](https://longbridge.com/en/quote/ATUS.US.md)
- [OPTU.US - Optimum Communications](https://longbridge.com/en/quote/OPTU.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 投资大佬德鲁肯米勒：我的优势不是智商，而是果断扣动扳机，卖飞英伟达 “肠子都悔青了” | 摩根士丹利《经验之谈》中，德鲁肯米勒认为其真正优势是 “扣动扳机” 的果断，以及从索罗斯学到的精髓：关键不在于对错，而在于对时赚多少、错时亏多少。他坦言 “逆向投资被高估”，认为群众 80% 的时间是对的，关键在于避开那 20% 的毁灭性时 | [Link](https://longbridge.com/en/news/277289579.md) |
| 美国伍德马克｜10-Q：2026 财年 Q3 营收 3.24 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/277098019.md) |
| “彻底失望”！德银首次下调诺和诺德评级 | 德意志银行首次下调诺和诺德股票评级至 “持有”，因其减肥药 CagriSema 在临床试验中表现不佳，导致市场抛售，股价暴跌 16%。摩根大通也下调评级并大幅削减销售预期，华尔街对该股的看涨比例降至数年最低，显示出对诺和诺德中期前景的悲观情 | [Link](https://longbridge.com/en/news/276727300.md) |
| 塞德斯医疗｜8-K：2025 财年 Q4 营收 12.1 万美元 |  | [Link](https://longbridge.com/en/news/276936516.md) |
| 礼来升级 Zepbound 巩固优势、一支用整月！诺和诺德新药临床失利股价暴跌 | 礼来周一推出 Zepbound 多剂量 KwikPen 注射装置，患者仅需一支笔即可完成一个月四次给药，最低月价 299 美元，并已获 FDA 批准扩展标签。受此消息提振，礼来股价盘中涨超 5%。与此同时，竞争对手诺和诺德的下一代减肥药 C | [Link](https://longbridge.com/en/news/276630276.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.